Home | Cellectis
...Cellectis gene-edits ?Chimeric Antigen Receptor? (CAR) T-cells from healthy donors into ?off-the-shelf? immunotherapy product candidates that are designed to work for the largest number of patients. It?s the difference between being an off-the-shelf product and a service in which each treatment has to be custom-made. This same technology, developed by Cellectis, could help in ......
https://www.cellectis.com/
Investors | Cellectis
...Cellectis is a clinical-stage biopharmaceutical company developing the Next-Generation CAR T-Cells to Cure Cancer....
https://www.cellectis.com/en/investors/
About - Cellectis
...Cellectis is a clinical-stage biopharmaceutical company developing the Next-Generation CAR T-Cells to Cure Cancer....
https://www.cellectis.com/en/about
Careers - Cellectis
...Cellectis is a clinical-stage biopharmaceutical company developing the Next-Generation CAR T-Cells to Cure Cancer....
https://www.cellectis.com/en/careers/
Investisseur | Cellectis
...Cellectis is a clinical-stage biopharmaceutical company developing the Next-Generation CAR T-Cells to Cure Cancer....
https://www.cellectis.com/fr/investors
Main Product Candidates | Cellectis
...Cellectis is a clinical-stage biopharmaceutical company developing the Next-Generation CAR T-Cells to Cure Cancer....
https://www.cellectis.com/en/products/product-candidates
Press | Cellectis
...Cellectis is a clinical-stage biopharmaceutical company developing the Next-Generation CAR T-Cells to Cure Cancer....
https://www.cellectis.com/en/press
Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results ...
...New York, NY ? March 12, 2026 - Cellectis (the ?Company?) (Euronext Growth: ALCLS, NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the fourth quarter and full year 2025 ending December ......
https://www.cellectis.com/en/press/cellectis-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-19-2026/
Cellectis publie ses résultats financiers du quatričme trimestre 2025 ...
...Cellectis publie ses résultats financiers du quatričme trimestre 2025 et de l?exercice 2025 et une mise ā jour de ses activités Publié le 19 mars 2026...
https://www.cellectis.com/fr/press/cellectis-publie-ses-resultats-financiers-du-quatrieme-trimestre-2025-et-de-lexercice-2025-et-une-mise-a-jour-de-ses-activites
Cellectis Announces 2026 Strategy and Catalysts
...New York, NY ? January 8, 2026 - Cellectis (the ?Company?) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today outlined its strategic priorities and key catalysts expected for 2026....
https://www.cellectis.com/en/press/cellectis-announces-2026-strategy-and-catalysts/
Åby Åbyggeby Åbytorp Åhus Åkarp Åkers styckebruk Åkersberga Ålberga Åled Ålem Åmmeberg Åmot Åmotfors Åmsele Åmynnet Åmål Ånge Ånäset Åre Årjäng Årstad Årsunda Åryd Ås Åsa Åsarne Åsarp Åsbro Åsby Åseda Åsele Åselstad Åsen Åsenhöga Åsensbruk Åshammar Åsljunga Åstol Åstorp Åtorp Åtvidaberg